Abstract
D&MD' s Transdermal & Transmucosal Delivery of Therapeutics, 2nd Edition market analysis report estimates the transdermal/transmucosal drug delivery market is poised for growth through 2010. This report highlights the technologies and drugs currently available for transdermal, buccal and intranasal routes of administration as well as an analysis of the potential market for drug delivery. A summary of the intellectual property landscape in this area, profiles of companies invested in transdermal and transmucosal drug delivery and interviews with key industry players round out this comprehensive report.
Table of Contents
CHAPTER 1: EXECUTIVE SUMMARY
CHAPTER 2: BASIC FACTS AND CONSIDERATIONS CONCERNING TRANSDERMAL AND TRANSMUCOSAL DELIVERY
- Structure of Skin and Mucosa
- The Skin- Man' s Largest Organ and its Tasks
- State and Trait Parameters for Skin Absorption
- Mucosal Sites as Differential Ports of Absorption
- Circumventing Bioavailability Issues
- Transdermal Delivery for Poorly Soluble Compounds
- Avoiding the Liver
- When Does TD/TM Delivery Make Sense?
- Pharmacological Rationale
- Convenience versus Predictability
- Economical Considerations
- Models for Transdermal and Transmucosal Absorption Testing and Optimization
- In Vitro Testing
- In Vivo Testing
CHAPTER 3: DEVICES AND FORMULATIONS
- Passive Transdermal and Transmucosal Systems
- Basic Types of Transdermal Patches
- Topical Formulations: Gels, Liposome Emulsions, and Nanoparticles
- Solutions for Oral Resorption
- Solutions for Nasal Resorption
- Examples of Delivery Formulation Approaches
- Active Transdermal Delivery- A Niche Application with Increasing Potential
- Delivery Systems Technologies in Development
- Ionthophoretic Patches
- Poration Technologies
- Other Technologies
- Applications for Nanomaterials
- Targeted Drug Delivery
- Solubilizing Pre-existing Drugs and Enhancing Controlled Drug Delivery
- Nanocochleate Formulations, Process of Preparation and Method of Delivery
of Pharmaceutical Agents
- Abstract
- Bioadhesive Progressive Hydration Tablets
- Abstract
CHAPTER 4: TRADITIONAL AND EMERGING THERAPEUTIC APPLICATIONS AND THEIR MARKETS
- Global Launched Transdermal Products
- Global Launched Transmucosal Products
- Examples of Specific Applications
- Organic Nitrate Compounds for Angina
- Oral Mucosal Nitroglycerin Products for Angina Attack Abrogation
- Acute Seizures
- Chronic Severe Pain
- Duragesic- The Flagship Transdermal Pain Product and its Competitors
- Other Fentanyl Products
- Actiq, A Supplemental Quick-Release Product for Breakthrough Pain
- Transdermal Non-Steroidal Antirheumatic Drugs for Less Severe Pain
- Migraine
- Hypertension
- Smoking Cessation and Alcohol Abuse
- Nicotine Patches- A Big Drugstore Seller
- Transdermal and Flash Release Systems for Alcohol Craving
- Hormonal Treatments
- Contraception
- Peri- and Postmenopausal Symptoms
- Osteoporosis
- Female Sexual Dysfunction
- Male Androgen Deficiency
- Erectile Dysfunction
- Diabetes- An Emerging Indication for Transmucosal Delivery?
- Neurology and Psychiatry
- Overactive Bladder
- Parkinson' s Disease
- Multiple Sclerosis
- Dementia
- Depression
- Psychosis
- Attention Deficit/Hyperactivity Disorder
CHAPTER 5: TRANSDERMAL AND TRANSMUCOSAL PIPELINE
- Transdermal Pipeline
- Products in Registration
- Products in Pre-registration
- Products in Phase III Clinical Trials
- Transmucosal Pipeline
- Products in Registration
- Products in Pre-registration:
- Products in Phase III Clinical Trials:
CHAPTER 6: THE TRANSDERMAL AND TRANSMUCOSAL MARKET OVERVIEW AND OUTLOOK
CHAPTER 7: COMPANY PROFILES
- Bentley
- BioDelivery Sciences
- Britannia
- BTG
- Cephalon
- Columbia Laboratories
- Cytokine PharmaSciences
- Dainippon
- Ethypharm
- Generex
- Intranasal Technologies
- Mochida
- Naryx
- Nastech
- OptiNose
- Orexo
- Questcor
- Shin Nippon
- Sosei
- Unigene
- Vernalis
- Vivus
- West Pharmaceutical Services
TABLE OF EXHIBITS
- Exhibit 2.1 A Schematic Representation of the Human Skin
- Exhibit 2.2 Enterohepatic Circulation and the "First-Pass Effect"
- Exhibit 2.3 Typical Plasma Concentrations over Time for a Drug after Oral and Transdermal Delivery.
- Exhibit 3.1 Representations of Drug-in-Adhesive, Reservoir, and Matrix TTS Solutions
- Exhibit 3.2 ALZA' s Active Trandermal Patch, E-TRANSR
- Exhibit 3.3 How the Vyteris Iontophoretic Patch Works
- Exhibit 3.4 CHADD Heating Unit Appication
- Exhibit 3.5 Examples of Launched and Pre-approval Transdermal and Transmucosal Formulations Incorporating Nanomaterials
- Exhibit 4.1 Global Launched Transdermal Products By Company
- Exhibit 4.2 Global Launched Transdermal Products By Therapy
- Exhibit 4.3 Global Launched Transmucosal Products By Company
- Exhibit 4.4 Global Launched Transmucosal Products By Therapy
- Exhibit 4.5 Selected Major Brands of Organic Nitrate Transdermal Systems
- Exhibit 4.6 Selected Major Brands of Nitroglycerol Sublingual, and Buccal Spray Products
- Exhibit 4.7 Performance of Duragesic in the US Sustained Release Opioid Market, 2000- 2003
- Exhibit 4.9 Alza Corp.' s E-TRANSR PCTS Device
- Exhibit 4.10 Transdermal and Pernasal Patents for Approved Cholinesterase Inhibitors
- Exhibit 5.1 Transdermal Product Pipeline by Company
- Exhibit 5.2 Transdermal Product Pipeline by Therapy
- Exhibit 5.3 Transmucosal Product Pipeline by Company
- Exhibit 5.4 Transmucosal Product Pipeline by Therapy
- Exhibit 6.1 Recent US Retail Sales of Transdermal and Transmucosal Drugs
